CYRX / Cryoport, Inc.'s (CYRX) CEO Jerrell Shelton on Q1 2022 Earnings Call Transcript

Cryoport released preliminary Q2 results, projecting sales to fall behind The Street's estimates. Lower demand for Cryoport's capital equipment and de more_horizontal

Cryoport downgraded annual guidance. The company has seen a slowdown in orders from gene therapy and cell therapy clients. more_horizontal

CryoPort (NASDAQ: CYRX ) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for the second qua more_horizontal

Shares of Cryoport Inc. CYRX, +3.58% fell 29% in premarket trading on Thursday after the life-science logistics company issued a revenue warning, noti more_horizontal

Cryoport, Inc. is well-positioned to benefit from the growth in the cell and gene therapy industry due to its dominant position in the cold-chain logi more_horizontal

Cryoport, Inc. (NASDAQ:CYRX ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Sh more_horizontal

Cryoport, Inc. (NASDAQ:CYRX ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA J more_horizontal

Cryoport has been punished over the last 12 months amid a number of downside catalysts. Shares have recently curled up off 52-week lows, asking the qu more_horizontal